Prodosmo et al. Journal of Experimental & Clinical Cancer Research (2016) 35:185
DOI 10.1186/s13046-016-0459-z

Journal of Experimental & Clinical Cancer Research

ERRATUM

Open Access

Erratum to: Detection of *ATM* germline variants by the p53 mitotic centrosomal localization test in *BRCA1/2*-negative patients with early-onset breast cancer

Andrea Prodosmo[1], Amelia Buffone[4], Manlio Mattioni[1], Agnese Barnabei[3], Agnese Persichetti[3,4], Aurora De Leo[3], Marialuisa Appetecchia[3], Arianna Nicolussi[11], Anna Coppa[11], Salvatore Sciacchitano[5], Carolina Giordano[6], Paola Pinnarò[6], Giuseppe Sanguineti[6], Lidia Strigari[7], Gabriele Alessandrini[8], Francesco Facciolo[8], Maurizio Cosimelli[9], Gian Luca Grazi[9], Giacomo Corrado[10], Enrico Vizza[10], Giuseppe Giannini[2,4*] and Silvia Soddu[1*]

Erratum

In original publication of this article [1], the data for "Pat#7" in Additional file 1 was listed as "c.4436+24G>A" in the "Nucleotide change" column. Instead, the number should have been c.4436+24A>G.

Additional file

Additional file 1: Characteristics of ATM variants. (DOCX 16 kb)

Author details
[1]Unit of Cellular Networks and Molecular Therapeutic Targets, Department of Research, Advanced Diagnostic, and Technological Innovation, Regina Elena National Cancer Institute – IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy. [2]Istituto Pasteur-Fondazione Cenci Bolognetti, Department of Molecular Medicine, University La Sapienza, Rome, Italy. [3]Endocrinology Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS, Rome, Italy. [4]Department of Molecular Medicine, University La Sapienza, Rome, Italy. [5]Department of Clinical and Molecular Medicine, University La Sapienza, Laboratorio di Ricerca Biomedica, Fondazione Università Niccolò Cusano per la Ricerca Medico Scientifica, Rome, Italy. [6]Radiotherapy Unit, Department of Research, Advanced Diagnostic, and Technological Innovation, Regina Elena National Cancer Institute - IRCCS, Rome, Italy. [7]Medical Physics Unit, Department of Research, Advanced Diagnostic, and Technological Innovation, Regina Elena National Cancer Institute – IRCCS, Rome, Italy. [8]Toracic Surgery Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS, Rome, Italy. [9]Hepato-pancreato-biliary Surgery Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS, Rome, Italy. [10]Gynecological Oncology Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS, Rome, Italy. [11]Department of Experimental Medicine, Sapienza University of Rome, Policlinico Umberto I, Viale Regina Elena, 32400161 Rome, Italy.

* Correspondence: giuseppe.giannini@uniroma1.it; silvia.soddu@ifo.gov.it
[2]Istituto Pasteur-Fondazione Cenci Bolognetti, Department of Molecular Medicine, University La Sapienza, Rome, Italy
[1]Unit of Cellular Networks and Molecular Therapeutic Targets, Department of Research, Advanced Diagnostic, and Technological Innovation, Regina Elena National Cancer Institute – IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy

Received: 14 November 2016 Accepted: 17 November 2016
Published online: 28 November 2016

Reference

1. Prodosmo A, et al. Detection of *ATM* germline variants by the p53 mitotic centrosomal localization test in *BRCA1/2*-negative patients with early-onset breast cancer. J Exp Clin Cancer Res. 2016;35:135. doi:10.1186/s13046-016-0410-3.